University Hospital Giessen Performs First Minimally Invasive, Robotic-Assisted Coronary Intervention in Germany

Siemens HealthineersThe University Hospital Giessen is the first hospital in Germany where a robotic system assists in a minimally invasive procedure to place a stent into a narrowed coronary artery to reopen it. This percutaneous coronary intervention (PCI) was carried out by the team of Prof. Holger Nef, Deputy Clinical Director Medical Clinic I, Cardiology and Angiology, University Giessen. To control interventional devices, doctors use the endovascular robotic system, CorPath® GRX (1) from Corindus, a Siemens Healthineers company, together with an Artis angiography system from Siemens Healthineers.

"Detailed imaging in combination with robotic-assisted intervention can provide increased precision to minimally invasive therapy. Especially complex procedures can be standardized and potentially provide better clinical results. I am very pleased that we were able to successfully use our imaging system and endovascular robotic platform at the University Hospital Giessen and Marburg in a procedure," said Doris Pommi, General Manager Cardiovascular Care at Siemens Healthineers.

Corindus' robotic system allows physicians to precisely control catheters, guidewires, balloons and stents with the help of integrated imaging for minimally invasive procedures. The doctor does not have to be physically next to the angiography table as usual, but can control the procedure via the system’s control module and is thus exposed to less radiation.

"The robotic system allows the precise positioning of interventional devices. This is crucial for the procedural success of the PCI procedure and can help improve long-term patient benefits. If coronary lesions are not fully covered by stents, this is a significant risk factor for follow-up interventions caused by re-stenosis," said Prof. Christian Hamm, Clinic Director Medical Clinic I, Cardiology/Angiology, University Giessen.

Technical advances in interventional cardiology can make it possible to successfully perform even more complex procedures routinely, like multi-vascular diseases, main stem stenosis, bifurcation stenosis or even re-openings of chronic closures. "Especially in these interventions, precision through robotic support, as well as the reduction of radiation exposure, can be of fundamental importance," said Prof. Holger Nef.

Coronary heart disease is one of the most common cardiovascular diseases in Western industrialized nations. Its consequences, such as acute heart attacks, are among the most common causes of death in Germany. In the treatment of acute and chronic coronary syndrome, PCI with stent implantation has established itself as the gold standard and is recommended in the European treatment guidelines.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.

About Corindus

Corindus, a Siemens Healthineers company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world.

1. The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. Detailed information is available from the local Siemens Healthineers organization.

Most Popular Now

West Midlands to Digitally Transform Can…

NHS patients throughout the West Midlands are to benefit from a digital pathology programme, designed to help reduce cancer backlogs, transform services, and improve the speed and accuracy of cancer...

AI Transforms Smartwatch ECG Signals int…

A study published in Nature Medicine reports the ability of a smartwatch ECG to accurately detect heart failure in nonclinical environments. Researchers at Mayo Clinic applied artificial intelligence (AI) to...

Siemens Healthineers Splits Fast-Growing…

Siemens Healthineers is splitting its Asia Pacific operations into two to allow both China and the rest of the region to achieve their full potential. China, now its own region...

Siemens Healthineers Presents Two Revolu…

7 Tesla (T) Magnetom Terra.X(1) will offer excellent imaging of even the smallest structures 3T Magnetom Cima.X(2) more than doubles the gradient amplitude(3) AI algorithms which can reduce scanning...

3D Protein Structure Predictions Made by…

In a living being, proteins make up roughly everything: from the molecular machines running every cell's metabolism, to the tip of your hair. Encoded in the DNA, a protein may...

New Group to Advance Digital Twins in He…

EDITH (Ecosystem for Digital Twins in Healthcare) Coordination and Support Action (CSA) - a group made up of numerous internationally renowned research institutions, professional associations, companies, and hospitals of excellence...

Willingness to Use Video Telehealth Incr…

Americans' use and willingness to use video telehealth has increased since the beginning of the COVID-19 pandemic, rising most sharply among Black Americans and people with less education, according to...

Evaluating Use of New AI Technology in D…

Published in the Journal of the American Medical Informatics Association, University of Minnesota researchers led a study evaluating federated learning variations for COVID-19 diagnosis in chest x-rays. Federated learning is...

DMEA Call for Papers: Supporting Digital…

25 - 27 April 2023, Berlin, Germany. Health meets digitalisation: from 25 to 27 April 2023 at DMEA - Connecting Digital Health, all actors aiming to promote health IT will be...

Machine Learning can Help Predict Patien…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at the Johns Hopkins...

MEDICA 2022 and COMPAMED 2022: Internati…

14 - 17 November 2022, Düsseldorf, Germany. Next week sees the return of the date marked in extra thick outline in many yearly calendars of the international health and medical technology...

MEDICA and COMPAMED Present Themselves a…

14 - 17 November 2022, Düsseldorf, Germany. MEDICA and COMPAMED continue to develop in an extremely vital manner. The world's leading medical trade fair and the international No. 1 for the...